Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PelvEx II: Induction Chemotherapy Plus Chemoradiotherapy vs Chemoradiotherapy Alone in Locally Recurrent Rectal Cancer
2024-512526-28-00Phase 3Authorised
- Sponsor
- Catharina Ziekenhuis
- Start
- Apr 2024
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised, open-label trial of capecitabine, irinotecan, fluorouracil, tegafur, folinic acid and 1 more in rectal cancer (2 arms), sponsored by Catharina Ziekenhuis. Primary endpoint: Rate of clear resection margins after surgery. Planned start Apr 2024; status: authorised.
02
Drugs
capecitabineirinotecanfluorouraciltegafurfolinic acid
03
Conditions
rectal cancer
Beyond the preview
Go deeper on 2024-512526-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512526-28-00.